Your browser doesn't support javascript.
Assessment of Predictors for SARS-CoV-2 Antibodies Decline Rate in Health Care Workers after BNT162b2 Vaccination-Results from a Serological Survey.
Zacks, Nadav; Bar-Shai, Amir; Levi, Hezi; Breslavsky, Anna; Maayan, Shlomo; Evgenia, Tsyba; Feitelovich, Shlomo; Wand, Ori; Schaffer, Moshe; Sherer, Yaniv; Givaty, Gili; Tzurel Ferber, Anat; Michael, Tal; Bilenko, Natalya.
  • Zacks N; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
  • Bar-Shai A; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
  • Levi H; Pulmonary Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Breslavsky A; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
  • Maayan S; Division of Infectious Diseases, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Evgenia T; Pulmonary Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Feitelovich S; Division of Infectious Diseases, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Wand O; Division of Infectious Diseases, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Schaffer M; Laboratory Division, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Sherer Y; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
  • Givaty G; Pulmonary Department, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Tzurel Ferber A; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
  • Michael T; Department of Oncology, Barzilai University Medical Centre, Ashkelon 7830604, Israel.
  • Bilenko N; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 84101, Israel.
Vaccines (Basel) ; 10(9)2022 Sep 01.
Article in English | MEDLINE | ID: covidwho-2010328
ABSTRACT

BACKGROUND:

SARS-CoV-2 is a novel human pathogen causing Coronavirus Disease 2019 that has caused widespread global mortality and morbidity. Since health workers in Israel were among the first to be vaccinated, we had a unique opportunity to investigate the post-vaccination level of IgG anti-S levels antibodies (Abs) and their dynamics by demographic and professional factors.

METHODS:

Prospective Serological Survey during December 2020-August 2021 at Barzilai Medical Center among 458 health care workers (HCW) followed for 6 months after the second BNT162b2 vaccine dose.

RESULTS:

Antibody levels before the second dose, and 30, 90 and 180 days after were 57.1 ± 29.2, 223 ± 70.2, 172.8 ± 73.3 and 166.4 ± 100.7 AU/mL, respectively. From GEE analysis, females had higher Abs levels (ß = 26.37 AU/mL, p = 0.002). Age was negatively associated with Abs, with a 1.17 AU/mL decrease for each additional year (p < 0.001). Direct contact with patients was associated with lower Abs by 25.02 AU/mL (p = 0.009) compared to working with no such contact. The average decline rate overall for the study period was 3.0 ± 2.9 AU/mL per week without differences by demographic parameters and was faster during the first 3 months after vaccination than in the subsequent 3 months.

CONCLUSIONS:

All demographic groups experienced a decline in Abs over time, faster during the first 3 months. Findings of overall Abs lower in males, workers with direct contact with patients, and older workers, should be considered for policy-making about choosing priority populations for additional vaccine doses in hospital settings.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091443

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Vaccines10091443